• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Patient-reported outcomes for multicentric Castleman's disease in a randomized, placebo-controlled study of Siltuximab.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    van Rhee, F
    Rothman, M
    Ho, K
    Fleming, S
    Wong, R
    Fosså, A
    Dispenzieri, A
    Cavet, James
    Munshi, N
    Vermeulen, J
    Casper, C
    Show allShow less
    Affiliation
    Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA
    Issue Date
    2015
    
    Metadata
    Show full item record
    Abstract
    Multicentric Castleman's disease (MCD) is a rare lymphoproliferative disorder driven by dysregulated interleukin-6 production. MCD has a poor prognosis, and treatment is generally noncurative and aimed at symptom relief. Siltuximab is a novel, monoclonal interleukin-6 antibody recently shown to be effective in a registration clinical trial. MCD symptoms, such as fatigue, pain, and weakness, are most appropriately quantified using patient-reported outcome (PRO) measures. We assessed the effect of siltuximab on patient perception of symptoms, functional status, and wellbeing using PRO instruments.
    Citation
    Patient-reported Outcomes for Multicentric Castleman's Disease in a Randomized, Placebo-controlled Study of Siltuximab. 2015, 8 (2):207-16 Patient
    Journal
    The Patient
    URI
    http://hdl.handle.net/10541/554158
    DOI
    10.1007/s40271-015-0120-5
    PubMed ID
    25736164
    Type
    Article
    Language
    en
    ISSN
    1178-1653
    ae974a485f413a2113503eed53cd6c53
    10.1007/s40271-015-0120-5
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease.
    • Authors: Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC, Wittenberg GM, Chen G
    • Issue date: 2017 Nov
    • Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
    • Authors: van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho SG, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C
    • Issue date: 2014 Aug
    • A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
    • Authors: van Rhee F, Casper C, Voorhees PM, Fayad LE, van de Velde H, Vermeulen J, Qin X, Qi M, Tromp B, Kurzrock R
    • Issue date: 2015 Oct 6
    • Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease.
    • Authors: Vernon M, Robinson D Jr, Trundell D, Ishak J, Jen MH, Brazier J
    • Issue date: 2016 Jul
    • Clinical development of siltuximab.
    • Authors: Davis CC, Shah KS, Lechowicz MJ
    • Issue date: 2015 Jul
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.